CN EN
BioDuro-Sundia
A stellar compliance record following global standards
BioDuro-Sundia, an Advent International portfolio company is a trusted, leading contract research, development, and manufacturing organization (CRDMO) with over 28 years of expertise. Global headquarter in Irvine, California, our global presence spans 7 sites across 6 cities, totaling nearly 3,000 employees. Specializing in small and large molecule discovery, development, scale-up and manufacturing, we offer fully integrated services from target identification to commercial drug product manufacturing.
Learn more
Fully Integrated CRDMO
One stop shop built to accelerate your timelines
Discovery
Hit Generation
Lead Optimization
Candidate Selection
Learn more
Drug Substance
Scale Up g → kg
API, RSMs & Intermediates
IND Filing (FDA, NMPA and others)
Learn more
Drug Product
Solubility Enhancement
Solid Oral Dosage Forms
Clinical & Commercial
Learn more
Platforms
Cutting-edge platforms and integrated solutions for first-in-class and innovative drug discovery, development and manufacturing
Learn more
Discover drugs faster with our comprehensive
in vitro evaluation platform
Bioavailability enhancement
Integrated services under one roof: synthetic chemistry, biology, DMPK, more.
Our one stop shop platform seamlessly
integrates preclinical research services
Find your next hit with the BioDuro-Sundia
fragment screening platform
Tailored engine for small molecular drug discovery
Unlock exponential possibilities screening billions of small molecules
Advanced preclinical models for NASH
Clinical relevance, shortened timelines
Quick collection with vast number
of compounds to speed drug discovery
Delayed, sustained, and custom release
News & Resources
The latest news about BioDuro-Sundia
Learn more
Company News
BioDuro-Sundia’s Partner, DigmBio Announced IND Clearance from Korea MFDS for its Selective PARP1 Inhibitor DM5167
Shanghai, March 26, 2024 – BioDuro-Sundia's partner, DigmBio, a South Korean biotechnology company, announced its selective PARP1 inhibitor for the treatment of triple-negative breast cancer has b
March 26, 2024
Work and careers
Build your career with BioDuro-Sundia

Our customer-oriented, science-driven, flexible, and people-focused culture enables us to provide top-tier integrated service as well as attract and retain talents, ensuring high-quality value delivery.

Learn more
Register Now!
Webinar: New Modality - Peptides Innovations and a Comprehensive Synthetic Peptide Drug Discovery Platform
June 19, 2024 at 10am ET / 07am PT / 04pm CET
View more